FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283466180> ?p ?o ?g. }

• W4283466180 endingPage "762" @default.
• W4283466180 startingPage "754" @default.
• W4283466180 abstract "The RAID (Ranolazine Implantable Cardioverter-Defibrillator) randomized placebo-controlled trial showed that ranolazine treatment was associated with reduction in recurrent ventricular tachycardia (VT) requiring appropriate implantable cardioverter-defibrillator (ICD) therapy. This study aimed to identify groups of patients in whom ranolazine treatment would result in the highest reduction of ventricular tachyarrhythmia (VTA) burden. Andersen-Gill analyses were performed to identify variables associated with risk for VTA burden among 1,012 patients enrolled in RAID. The primary endpoint was VTA burden defined as VTA episodes requiring appropriate treatment. Multivariate analysis identified 7 factors associated with increased VTA burden: history of VTA, age ≥65 years, New York Heart Association functional class ≥III, QRS complex (≥130 ms), low ejection fraction (<30%), atrial fibrillation (AF), and concomitant antiarrhythmic drug (AAD) therapy. The effect of ranolazine on VTA burden was seen among patients without concomitant AAD therapy (HR [HR]: 0.68; 95% CI: 0.55-0.84; P < 0.001), whereas no effect was seen among those who are concomitantly treated with other AADs (HR: 1.33; 95% CI: 0.90-1.96; P = 0.16); P = 0.003 for interaction. In patients with cardiac resynchronization therapy (CRT) ICDs, ranolazine treatment was associated with a 36% risk reduction for VTA recurrence (HR: 0.64; 95% CI: 0.47-0.86; P < 0.001), whereas among patients with ICDs without CRT no significant effect was noted (HR: 0.94; 95% CI: 0.74-1.18; P = 0.57); P = 0.047 for interaction. In patients with high risk for VTA, ranolazine is effective in reducing VTA burden, with significantly greater effect in CRT-treated patients, those without AF, and those not treated with concomitant AADs. In patients already on AADs or those with AF, the addition of ranolazine did not affect VTA burden. (Ranolazine Implantable Cardioverter-Defibrillator Trial [RAID]; NCT01215253)" @default.
• W4283466180 created "2022-06-26" @default.
• W4283466180 creator A5002121570 @default.
• W4283466180 creator A5004707994 @default.
• W4283466180 creator A5005973866 @default.
• W4283466180 creator A5006422878 @default.
• W4283466180 creator A5007803409 @default.
• W4283466180 creator A5008613276 @default.
• W4283466180 creator A5016673974 @default.
• W4283466180 creator A5018802200 @default.
• W4283466180 creator A5020531014 @default.
• W4283466180 creator A5030159733 @default.
• W4283466180 creator A5041240717 @default.
• W4283466180 creator A5047355787 @default.
• W4283466180 creator A5055213891 @default.
• W4283466180 creator A5059052503 @default.
• W4283466180 creator A5077082770 @default.
• W4283466180 creator A5077374974 @default.
• W4283466180 creator A5085273930 @default.
• W4283466180 date "2022-06-01" @default.
• W4283466180 modified "2023-09-27" @default.
• W4283466180 title "Reduction in Ventricular Tachyarrhythmia Burden in Patients Enrolled in the RAID Trial" @default.
• W4283466180 cites W1965315863 @default.
• W4283466180 cites W1970873940 @default.
• W4283466180 cites W2015108591 @default.
• W4283466180 cites W2036033980 @default.
• W4283466180 cites W2049708544 @default.
• W4283466180 cites W2078647897 @default.
• W4283466180 cites W2086362149 @default.
• W4283466180 cites W2087388640 @default.
• W4283466180 cites W2101541776 @default.
• W4283466180 cites W2138736911 @default.
• W4283466180 cites W2141895646 @default.
• W4283466180 cites W2158671861 @default.
• W4283466180 cites W2159446154 @default.
• W4283466180 cites W2161984704 @default.
• W4283466180 cites W2171402333 @default.
• W4283466180 cites W2221325490 @default.
• W4283466180 cites W2228458488 @default.
• W4283466180 cites W2290027246 @default.
• W4283466180 cites W2302036983 @default.
• W4283466180 cites W2528468257 @default.
• W4283466180 cites W2555434784 @default.
• W4283466180 cites W2598092556 @default.
• W4283466180 cites W2599761051 @default.
• W4283466180 cites W2609605008 @default.
• W4283466180 cites W2899590947 @default.
• W4283466180 cites W2979060055 @default.
• W4283466180 doi "https://doi.org/10.1016/j.jacep.2022.02.018" @default.
• W4283466180 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35738852" @default.
• W4283466180 hasPublicationYear "2022" @default.
• W4283466180 type Work @default.
• W4283466180 citedByCount "0" @default.
• W4283466180 crossrefType "journal-article" @default.
• W4283466180 hasAuthorship W4283466180A5002121570 @default.
• W4283466180 hasAuthorship W4283466180A5004707994 @default.
• W4283466180 hasAuthorship W4283466180A5005973866 @default.
• W4283466180 hasAuthorship W4283466180A5006422878 @default.
• W4283466180 hasAuthorship W4283466180A5007803409 @default.
• W4283466180 hasAuthorship W4283466180A5008613276 @default.
• W4283466180 hasAuthorship W4283466180A5016673974 @default.
• W4283466180 hasAuthorship W4283466180A5018802200 @default.
• W4283466180 hasAuthorship W4283466180A5020531014 @default.
• W4283466180 hasAuthorship W4283466180A5030159733 @default.
• W4283466180 hasAuthorship W4283466180A5041240717 @default.
• W4283466180 hasAuthorship W4283466180A5047355787 @default.
• W4283466180 hasAuthorship W4283466180A5055213891 @default.
• W4283466180 hasAuthorship W4283466180A5059052503 @default.
• W4283466180 hasAuthorship W4283466180A5077082770 @default.
• W4283466180 hasAuthorship W4283466180A5077374974 @default.
• W4283466180 hasAuthorship W4283466180A5085273930 @default.
• W4283466180 hasBestOaLocation W42834661801 @default.
• W4283466180 hasConcept C126322002 @default.
• W4283466180 hasConcept C142724271 @default.
• W4283466180 hasConcept C164705383 @default.
• W4283466180 hasConcept C168563851 @default.
• W4283466180 hasConcept C203092338 @default.
• W4283466180 hasConcept C204787440 @default.
• W4283466180 hasConcept C27081682 @default.
• W4283466180 hasConcept C2776331378 @default.
• W4283466180 hasConcept C2777093960 @default.
• W4283466180 hasConcept C2778198053 @default.
• W4283466180 hasConcept C2779161974 @default.
• W4283466180 hasConcept C2779177932 @default.
• W4283466180 hasConcept C2779384505 @default.
• W4283466180 hasConcept C2781005686 @default.
• W4283466180 hasConcept C71924100 @default.
• W4283466180 hasConcept C78085059 @default.
• W4283466180 hasConceptScore W4283466180C126322002 @default.
• W4283466180 hasConceptScore W4283466180C142724271 @default.
• W4283466180 hasConceptScore W4283466180C164705383 @default.
• W4283466180 hasConceptScore W4283466180C168563851 @default.
• W4283466180 hasConceptScore W4283466180C203092338 @default.
• W4283466180 hasConceptScore W4283466180C204787440 @default.
• W4283466180 hasConceptScore W4283466180C27081682 @default.
• W4283466180 hasConceptScore W4283466180C2776331378 @default.
• W4283466180 hasConceptScore W4283466180C2777093960 @default.
• W4283466180 hasConceptScore W4283466180C2778198053 @default.

• next